IPO of biologics division likely in next few years, says Biocon's Kiran Mazumdar Shaw
Updated : May 15, 2019 11:13 AM IST
Annualised numbers for biologics segment have almost doubled YoY: Biocon
Don't find it reasonable the way biologics business is being looked at: Biocon
Delivered strong growth in biosimilar segment in emerging markets: Biocon
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more